你可能會喜歡
Surreal to play a role in this relay race. Below proof that menin inhibition works. A new targeted therapy in leukemia published @Nature nature.com/articles/s4158… @MDAndersonNews
Menin inhibitors emerge as new treatment for advanced AML. Guest editorial by Ghayas Issa (@GhayasIssa, @MDAndersonNews). cancerletter.com/trials-and-tri…
"Our research confirmed the significant benefits and efficacy of this therapy for both adult and pediatric patients," says Dr. Ghayas Issa. @US_FDA has approved revumenib for some patients with relapsed or refractory acute leukemia: brnw.ch/21wOL2U @GhayasIssa #EndCancer
Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)
We’ve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration @GhayasIssa @MDAndersonNews
The first BTC trial to target AML MRD with combination of menin and BCL2 inhibition is now open! Huge team effort and more exciting trials for MRD to come. Goal is to better measure, understand and treat MRD
We’ve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration @GhayasIssa @MDAndersonNews
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute #Leukemia (AUGMENT-101): brnw.ch/21wM2Yh #leusm
Revumenib phase 2 for R/R KMT2Ar finally out! ORR 63%, CR/CRh 23%, MRD neg 70%. Result filed for FDA approval ascopubs.org/doi/10.1200/JC…
How long do you wait for leukemia fusion RT-PCR, FISH, cytogenetics? Bedside CRISPR-based detection of PML::RARA and BCR::ABL1 fusions as a point of care test, even on a dried blood spot, from #RahulVedula and @ColemanLindsley @DanaFarber #HemeNeoDivision ashpublications.org/blood/article-…
Menin inhibitors seek to debut as newest targeted therapy for leukaemia bit.ly/3xsRP99 Find out how small molecules that block a key protein–protein interaction could change the treatment landscape for many patients with acute leukaemias in this news article
👉👉Delighted to present results of an investigator-initiated trial of Pirto + Ven + Obin as firstline Rx of pts with #CLL at @EHA_Hematology #EHA2024 A thread 🧵
Asciminib frontline!
Presented at #ASCO24: ASC4FIRST: Asciminib, an agent that targets the myristoyl pocket of BCR::ABL, was compared with imatinib and with imatinib plus second-generation tyrosine kinase inhibitors. Outcomes were better with aciminib in both comparisons. nej.md/4bNNr3c
Nice! Congrats @DavidSeoMD!! Forgive you for missing eclipse events :)
Watch author @DavidSeoMD discuss his research article, Randomized phase 1b microbiome modulation trial in #melanoma, published simultaneously at #AACR24: vimeo.com/932607668/63ad… @MDAndersonNews
vimeo.com
Vimeo
Dr. Yongwoo David Seo: Randomized phase 1b microbiome modulation...
Watch author @DavidSeoMD discuss his research article, Randomized phase 1b microbiome modulation trial in #melanoma, published simultaneously at #AACR24: vimeo.com/932607668/63ad… @MDAndersonNews
vimeo.com
Vimeo
Dr. Yongwoo David Seo: Randomized phase 1b microbiome modulation...
Just published with the #AACR24 presentation, by @DavidSeoMD— Randomized Placebo-Controlled, Biomarker-stratified Phase 1b #Microbiome Modulation in #Melanoma: Impact of Antibiotic Pre-conditioning. bit.ly/4cIDANr @CSpencerPhD @JenWargoMD @MDAndersonNews
Wonderful editorial by Dr Bernt on Barajas et al showing the latest addition to the “club”. Eytan and I have been brewing this trial for a while and it’s finally about to open: menin inhibition for the HOX-high club (including UBTF-TD based on this work) classic.clinicaltrials.gov/ct2/show/NCT06…
dWIZ from the chemical biology wiz @jaybradner and team @Novartis. Amazing plenary!! #ASH2023
Menin inhibitors continue to show tremendous promise in AML w/ encouraging clinical activity as single agents and now in comb. w/ HMA’s + Ven in R/R AML w/ NPM1 or KMT2Ar. Great presentation by @GhayasIssa on SAVE trial. Hopeful these agents will make a huge impact in AML. #ASH23
Revumenib Combo Showcases Early Activity in Relapsed/Refractory AML @GhayasIssa @MDAndersonNews @ASH_Hematology #ASH23 #ASH2023 #leusm onclive.com/view/revumenib…
United States 趨勢
- 1. Texans 38.4K posts
- 2. Josh Allen 20.6K posts
- 3. Bills 133K posts
- 4. #MissUniverse 276K posts
- 5. Joe Brady 3,628 posts
- 6. Maxey 8,858 posts
- 7. Anderson 24K posts
- 8. #TNFonPrime 2,510 posts
- 9. Costa de Marfil 18.2K posts
- 10. McDermott 2,688 posts
- 11. Shakir 5,122 posts
- 12. Al Michaels N/A
- 13. Spencer Brown N/A
- 14. Ray Davis 2,191 posts
- 15. James Cook 5,305 posts
- 16. #BUFvsHOU 2,766 posts
- 17. Nico Collins 1,918 posts
- 18. Nick Caley N/A
- 19. Ryan Rollins 1,391 posts
- 20. Achilles 3,947 posts
你可能會喜歡
-
Nicholas Short MD
@NicholasShortMD -
Naval Daver, M.D.
@Daver_Leukemia -
Nitin Jain
@NitinJainMD -
Guillermo Garcia-Manero
@garciamanero -
Musa Yilmaz, MD
@MusaYilmazMD -
Fadi Haddad, MD
@FadiHaddad_MD -
Raajit Rampal, M.D.Ph.D.
@RaajitRampal -
Prithviraj Bose
@bose_prithviraj -
Jorge Cortes MD
@GCC_Cortes -
Society of Hematologic Oncology (SOHO)
@SocietyofHemOnc -
Sangeetha Venugopal MD,MS
@drsangeetmd -
Koichi Takahashi
@DrKTakahashi -
Dr. Uma Borate: Associate Professor
@beatalleukemia -
Jessica Altman, MD
@jaltmanmd -
Carmelo Gurnari
@CarmeloGurnari
Something went wrong.
Something went wrong.